OverviewSuggest Edit

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of products and procedures to transform the treatment of glaucoma. The Company has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to change the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent Trabecular Micro-Bypass Stent, its first MIGS device. The Company is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression.

TypePublic
Founded1998
HQSan Clemente, US
Websiteglaukos.com
Employee Ratings4.3

Latest Updates

Employees (est.) (Dec 2019)600(+38%)
Job Openings17
Revenue (FY, 2019)$237 M(+31%)
Share Price (Sept 2020)$48.8 (+3%)
Cybersecurity ratingBMore

Key People/Management at Glaukos

Thomas Burns

Thomas Burns

President, Chief Executive Officer
Chris Calcaterra

Chris Calcaterra

COO
Joseph Gilliam

Joseph Gilliam

Chief Financial Officer, Senior Vice President, Corporate Development
Robert Davis

Robert Davis

Senior Vice President, General Counsel and Quality Affairs
Michele Allegretto

Michele Allegretto

Senior Vice President, Human Resources
David Haffner

David Haffner

Senior Vice President, New Technologies
Show more

Glaukos Office Locations

Glaukos has offices in San Clemente, Atlanta, Birmingham, Chicago and in 16 other locations
San Clemente, US (HQ)
229 Avenida Fabricante
Atlanta, US
Atlanta, GA, USA
Birmingham, US
Birmingham, AL, USA
Chicago, US
Chicago, IL, USA
Cleveland, US
Cleveland, OH, USA
Columbus, US
Columbus, OH, USA
Show all (23)

Glaukos Financials and Metrics

Glaukos Revenue

Embed Graph
View revenue for all periods
Glaukos's revenue was reported to be $236.98 m in FY, 2019
USD

Revenue (Q2, 2020)

31.6m

Gross profit (Q2, 2020)

9.9m

Gross profit margin (Q2, 2020), %

31.3%

Net income (Q2, 2020)

(39.9m)

EBIT (Q2, 2020)

(47.2m)

Market capitalization (25-Sept-2020)

2.2b

Closing stock price (25-Sept-2020)

48.8

Cash (30-Jun-2020)

267.0m

EV

2.2b
Glaukos's current market capitalization is $2.2 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

71.7m114.4m159.3m181.3m237.0m

Cost of goods sold

13.0m16.2m21.1m25.1m38.6m

Gross profit

58.7m98.2m138.2m156.2m198.4m

Gross profit Margin, %

82%86%87%86%84%
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

17.8m19.0m23.1m28.6m29.6m35.9m41.3m40.4m40.1m43.2m43.9m54.0m58.6m58.5m55.3m31.6m

Cost of goods sold

3.3m3.3m3.1m4.4m3.9m5.2m5.5m5.7m5.8m6.2m6.0m7.1m7.9m7.7m32.5m21.7m

Gross profit

14.5m15.7m20.0m24.2m25.7m30.7m35.8m34.7m34.3m37.0m37.9m46.9m50.7m50.8m22.8m9.9m

Gross profit Margin, %

82%83%86%85%87%86%87%86%86%86%86%87%87%87%41%31%
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

21.6m6.5m24.5m29.8m62.4m

Accounts Receivable

7.5m14.3m16.7m18.7m38.4m

Prepaid Expenses

1.3m3.0m2.6m4.1m7.9m

Inventories

4.1m6.8m11.2m13.3m42.6m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(38.3m)4.5m(92.0k)(13.0m)15.4m

Depreciation and Amortization

7.8m4.7m5.5m6.3m6.3m

Inventories

(1.8m)(2.9m)(4.2m)(2.3m)4.1m

Accounts Payable

1.5m5.1m9.7m2.5m779.0k
USDQ2, 2015

Financial Leverage

1.4 x
Show all financial metrics

Glaukos Acquisitions / Subsidiaries

Company NameDateDeal Size
AvedroNovember 21, 2019$437.80 m

Glaukos Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

Glaukos Online and Social Media Presence

Embed Graph

Glaukos News and Updates

Glaukos /Avedro (GKOS) Alert: Investigation into the Glaukos Acquisition of Avedro; Avedro Investors Receiving Glaukos Shares Encouraged to Contact Johnson Fistel

SAN DIEGO, Aug. 18, 2020 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against Glaukos Corporation (NYSE: GKOS) ("Glaukos" or the "Company") for violations of federal securities laws. In November 2019, Glaukos completed its merger with...

AVEDRO, INC. SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces an Investigation of Avedro, Inc. (AVDR) Over the Proposed Merger of the Company with Glaukos Corporation

NEW YORK, Sept. 27, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating the proposed merger of Avedro, Inc. ("Avedro" or the "Company") (NASDAQ: AVDR) with Glaukos Corporation ("Glaukos"). Click here for more information:...

Glaukos Frequently Asked Questions

  • When was Glaukos founded?

    Glaukos was founded in 1998.

  • Who are Glaukos key executives?

    Glaukos's key executives are Thomas Burns, Chris Calcaterra and Joseph Gilliam.

  • How many employees does Glaukos have?

    Glaukos has 600 employees.

  • What is Glaukos revenue?

    Latest Glaukos annual revenue is $237 m.

  • What is Glaukos revenue per employee?

    Latest Glaukos revenue per employee is $395 k.

  • Who are Glaukos competitors?

    Competitors of Glaukos include Livanova, Alphatec Spine and CryoLife.

  • Where is Glaukos headquarters?

    Glaukos headquarters is located at 229 Avenida Fabricante, San Clemente.

  • Where are Glaukos offices?

    Glaukos has offices in San Clemente, Atlanta, Birmingham, Chicago and in 16 other locations.

  • How many offices does Glaukos have?

    Glaukos has 23 offices.